Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cintia Cruz

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 26, 2021
COVID-19 chemopreventionCintia Cruz, Nicholas J White
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 17, 2026
Pediatric Chagas diseaseFacundo Garcia-Bournissen, Cintia Cruz, Jaime Altcheh
British Journal of Clinical Pharmacology|July 1, 2026
Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort studyKouki Tomari, Ruud H J Verstegen, Cintia Cruz, et al.
Plos Neglected Tropical Diseases|September 22, 2025
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)Frauke Assmus, Cintia Cruz, James A Watson, et al.
The Lancet. Microbe|September 11, 2025
Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trialsJames A Watson, Cintia Cruz, Fabiana Barreira, et al.
BMC Infectious Diseases|January 15, 2024
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trialViravarn Luvira, William H K Schilling, Podjanee Jittamala, et al.
Elife|February 21, 2023
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)William H K Schilling, Podjanee Jittamala, James A Watson, et al.
The Lancet. Infectious Diseases|October 1, 2023
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trialWilliam H K Schilling, Podjanee Jittamala, James A Watson, et al.
The Journal of Infectious Diseases|July 20, 2023
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)Podjanee Jittamala, William H K Schilling, James A Watson, et al.
Eclinicalmedicine|February 3, 2025
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Podjanee Jittamala, Simon Boyd, William H K Schilling, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 26, 2021
COVID-19 chemopreventionCintia Cruz, Nicholas J White
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 17, 2026
Pediatric Chagas diseaseFacundo Garcia-Bournissen, Cintia Cruz, Jaime Altcheh
British Journal of Clinical Pharmacology|July 1, 2026
Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort studyKouki Tomari, Ruud H J Verstegen, Cintia Cruz, et al.
Plos Neglected Tropical Diseases|September 22, 2025
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)Frauke Assmus, Cintia Cruz, James A Watson, et al.
The Lancet. Microbe|September 11, 2025
Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trialsJames A Watson, Cintia Cruz, Fabiana Barreira, et al.
BMC Infectious Diseases|January 15, 2024
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trialViravarn Luvira, William H K Schilling, Podjanee Jittamala, et al.
Elife|February 21, 2023
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)William H K Schilling, Podjanee Jittamala, James A Watson, et al.
The Lancet. Infectious Diseases|October 1, 2023
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trialWilliam H K Schilling, Podjanee Jittamala, James A Watson, et al.
The Journal of Infectious Diseases|July 20, 2023
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)Podjanee Jittamala, William H K Schilling, James A Watson, et al.
Eclinicalmedicine|February 3, 2025
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Podjanee Jittamala, Simon Boyd, William H K Schilling, et al.
Pageof 1